A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
Pfizer
Miltenyi Biomedicine GmbH
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Kelonia Therapeutics, Inc.
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
New York Medical College
Columbia University
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
AIDS Malignancy Consortium
Nurix Therapeutics, Inc.
Verismo Therapeutics
Incyte Corporation
University of Utah
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Baylor College of Medicine
Janssen Research & Development, LLC
FBD Biologics Limited
Mayo Clinic
Janssen Research & Development, LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
TCRx Therapeutics Co.Ltd
Janssen Research & Development, LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Conjupro Biotherapeutics, Inc.
Memorial Sloan Kettering Cancer Center